Immunotherapy in Preoperative Treatment of Triple-Negative Breast Cancer

Locally advanced triple-negative breast cancer is treated with standard neoadjuvant (preoperative tumor-shrinking) chemotherapy. Adding immunotherapy pembrolizumab (Keyturuda) increases the pathological complete response rate by nearly 15%, according to clinical trial results presented at ESMO 2019.
Below are breast cancer types according to their biological characteristics:

Professor Schmid and colleagues in England conducted the placebo-controlled KEYNOTE-522 phase III clinical trial, enrolling previously untreated patients with stages T1c N1-2 or T2-4 N0-2, whose disease was not metastatic , with triple-negative breast cancer.
Patients were randomized into two arms: 784 received pembrolizumab every 3 weeks at 200 mg, and 390 received placebo. All received standard chemotherapy with 12 weeks of paclitaxel plus carboplatin, followed by 4 cycles of doxorubicin or epirubicin plus cyclophosphamide. After breast cancer surgery, all patients received adjuvant treatment with an additional 9 cycles of pembrolizumab or placebo until recurrence or unacceptable side effects. Patients were stratified by axillary involvement (negative or positive) and tumor size (T1 / T2 and T3 / T4).
The primary endpoint of KEYNOTE-522 is pathological complete response rate. The pathology result from breast cancer surgery shows how effective preoperative chemotherapy has been. If no cancer cells are found in surgical pathology after neoadjuvant treatment, this is called a pathological complete response. Previous studies had shown that patients achieving this response have a lower likelihood of cancer recurrence.
Study Results
- With median follow-up of 15.5 months, 602 patients were assessed for pathological complete response.
- The pathological complete response rate with pembrolizumab + chemotherapy was 64.8% , versus placebo + chemotherapy at 51.2% in the study.
- A striking finding was that regardless of PD-L1 status, pembrolizumab plus chemotherapy showed greater antitumor activity.
- In PD-L1-positive patients, pathological complete response was 68.9% with chemotherapy plus pembrolizumab, versus 54.9% with chemotherapy plus placebo. • In PD-L1-negative patients, these rates were 45.3% versus 30.3%.
Side Effects
Side effect rates were similar between arms and consistent with their known safety profiles. Serious treatment-related side effects (grade 3 or higher) occurred with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in 78.0%, versus 73.0% with placebo and chemotherapy. Mortality in the respective regimens was 0.4% and 0.3%.
In conclusion, based on data presented at the ESMO 2019 Congress, researchers concluded that neoadjuvant pembrolizumab plus chemotherapy significantly increased pathological complete response compared with standard chemotherapy in patients with early-stage triple-negative breast cancer.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.